tiprankstipranks
Trending News
More News >
Supernus Pharmaceuticals (SUPN)
NASDAQ:SUPN
US Market
Advertisement

Supernus Pharmaceuticals (SUPN) Ownership - Who Owns Supernus Pharmaceuticals?

Compare
517 Followers

Supernus Pharmaceuticals (SUPN) Ownership Overview

4.36%34.25%1.05%27.61%32.73%
1.05% Other Institutional Investors
27.61% ETFs
32.73% Public Companies and
Individual Investors
The ownership structure of Supernus Pharmaceuticals (SUPN) stock is a mix of institutional, retail, and individual investors. Approximately 62.90% of the company’s stock is owned by Institutional Investors, 4.36% is owned by Insiders, and 32.73% is owned by Public Companies and Individual Investors.
The ownership structure of Supernus Pharmaceuticals (SUPN) stock is a mix of institutional, retail, and individual investors. Approximately 35.30% of the company’s stock is owned by Institutional Investors, 4.36% is owned by Insiders, and 27.61% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Oct 10, 2025
xxxxxxxxxxxxx
$3029336
Oct 03, 2025
xxxxxxxxxxxxx
$91506
Oct 02, 2025
xxxxxxxxxxxxx
$1931116
Oct 01, 2025
xxxxxxxxxxxxx
$414371

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Jun 30, 2025
xxxxxxxxxxxxx
$330329
Jun 30, 2025
xxxxxxxxxxxxx
$376695
Jun 30, 2025
xxxxxxxxxxxxx
$1024526
Jun 30, 2025
xxxxxxxxxxxxx
$24364203

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
6,101,412Institution10.88%306,107,840
5,140,791Institution9.17%257,913,484
4,717,436Institution8.41%236,673,764
4,078,684Institution7.27%204,627,576
2,212,178Insider3.95%110,984,970
1,716,422Institution3.06%86,112,892
1,003,449Institution1.79%50,343,036
894,383Institution1.60%44,871,195
854,114Institution1.52%42,850,899
772,976Institution1.38%38,780,206

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
4,717,436Institution8.41%236,673,764
4,078,684Institution7.27%204,627,576
1,716,422Institution3.06%86,112,892
854,114Institution1.52%42,850,899
611,292Institution1.09%30,668,520
556,177Institution0.99%27,903,400
533,116Institution0.95%26,746,430
386,960Institution0.69%19,413,783
375,471Institution0.67%18,837,380
358,847Institution0.64%18,003,354

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
3,283,902Institution5.86%163,406,964
1,691,323Institution3.02%80,828,326
1,287,526Institution2.30%64,067,294
1,262,536Institution2.25%60,336,595
808,470Institution1.44%38,636,781
601,308Institution1.07%28,736,509
483,766Institution0.86%24,072,196
430,885Institution0.77%21,440,838
331,452Institution0.59%16,493,052
306,800Institution0.55%15,266,368

FAQ

Who Owns Supernus Pharmaceuticals (SUPN)?
According to the latest TipRanks data, approximately 1.05% of the company's stock is held by institutional investors, 4.36% is held by insiders, and 32.73% is held by retail investors.
    What percentage of Supernus Pharmaceuticals (SUPN) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 1.05% of Supernus Pharmaceuticals (SUPN) stock is held by institutional investors.
      What percentage of Supernus Pharmaceuticals (SUPN) stock is held by retail investors?
      According to the latest TipRanks data, approximately 32.73% of Supernus Pharmaceuticals (SUPN) stock is held by retail investors.
        Who owns the most shares of Supernus Pharmaceuticals (SUPN)?
        iShares owns the most shares of Supernus Pharmaceuticals (SUPN).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis